Atogepant, an oral drug approved to prevent migraine, appears to also alleviate migraine symptoms early after onset has begun. The findings were reported on December 23, 2024 in… read more.
A drug used to prevent migraine may also be effective in people with migraine who experience rebound headaches, according to a new study published in the June 26,… read more.
AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
